Researcher
Luc Mortelmans
- Disciplines:Other biological sciences, Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Faculty of Medicine (Faculty)
Member
From1 Oct 2012 → 30 Sep 2017 - Nuclear Medicine & Molecular Imaging (Division)
Member
From1 Oct 1999 → 30 Sep 2012
Projects
1 - 9 of 9
- Development and evaluation of PET ligands for the in vivo visualisation of phosphodiesterase type 5 (PDE5).From1 Jan 2012 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
- GMP lab for production of PET tracers for clinical and translational researchFrom15 Dec 2010 → 6 May 2018Funding: Hercules - Small and Medium size research infrastructure
- Molecular and functional imaging as a pivotal tool for translational medicine in the field of neuroscience and oncology: a platform creating a bridge between basic research, clinical development and industrial application.From1 Oct 2010 → 30 Sep 2014Funding: IOF - Industrial Research Fund
- Enhancing the diagnostic and quantitative value of emission tomography through the use of anatomical side-information during reconstruction.From1 Oct 2010 → 31 Jul 2016Funding: FWO fellowships
- Leuven Health Technology Centre (L-HTC)From1 Oct 2010 → 30 Nov 2021Funding: IOF - mandates, IOF - Industrial Research Fund
- Medical imagingFrom1 Jul 2009 → TodayFunding: IOF - mandates, IOF - Industrial Research Fund
- Euregional Pact II.From1 Apr 2009 → 31 Jan 2013Funding: Foreign foundations, funds with scientific view
- A phase I dose-escalation study to determine the maximum tolerated dose of radiotherapy, in combination with concomitant 5-FU chemptherapy, in patients with locally advanced rectal cancer with a positive circumferential resection margin (cCRM).From1 Jan 2009 → 31 Dec 2010Funding: Private funding of national origin - undefined
- Evaluation of molecular, dosimetric and ultrastructural imaging in the management of neuroendocrine tumors with Peptide Receptor Radionuclide Therapy: results of a prospective, monocentric, non-controlled phase II studyFrom1 Nov 2008 → 27 May 2015Funding: Nonprofit institution or equivalents
Publications
1 - 10 of 45
- Emergency Healthcare Providers' Perceptions of Preparedness and Willingness to Work during Disasters and Public Health Emergencies(2020)
Authors: Luc Mortelmans
- Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours(2016)
Authors: Sofie Van Binnebeek, Kristof Baete, Michel Koole, Felix Mottaghy, Paul Clement, Luc Mortelmans, Kris Bogaerts, Karin Haustermans, Kristiaan Nackaerts, Eric Van Cutsem, et al.
Pages: 900 - 9 - Evaluatie van moleculaire, dosimetrische en ultrastructurele beeldvorming in het beleid van neuro-endocriene tumoren, behandeld met Peptide Receptor Radionuclide Therapie: resultaten van een prospectieve, monocentrische, niet-gecontrolleerde fase II studie(2015)
Authors: Christophe Deroose, Eric Van Cutsem, Chris Verslype, Luc Mortelmans
- Individualized dosimetry-based activity reduction of (90)Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy(2014)
Authors: Sofie Van Binnebeek, Kristof Baete, Michel Koole, Felix Mottaghy, Paul Clement, Luc Mortelmans, Karin Haustermans, Eric Van Cutsem, Alfons Verbruggen, Kris Bogaerts, et al.
Pages: 1141 - 1157 - 18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study(2013)
Authors: Michel Koole, Cindy Casteels, Guy Bormans, Filip Claus, Evelyne Lerut, Hendrik Van Poppel, Steven Joniau, Herlinde Dumez, Karin Haustermans, Luc Mortelmans, et al.
Pages: 59 - In vitro and in vivo comparison of 18F and 123I-labeled ML10 with 68Ga-Cys2-AnxA5 for molecular imaging of apoptosis(2013)
Authors: Matthias Bauwens, Stijn Hendrickx, Yicheng Ni, Luc Mortelmans, Felix Mottaghy, Alfons Verbruggen
Pages: 187 - 200 - Significant impact of transient deterioration of renal function on dosimetry in PRRT(2013)
Authors: Sofie Van Binnebeek, Kristof Baete, Karin Haustermans, Luc Mortelmans, Eric Van Cutsem, Chris Verslype, Felix Mottaghy, Alfons Verbruggen, Christophe Deroose
Pages: 74 - 77 - Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model(2013)
Authors: Johan Swinnen, Evelyne Lerut, Michel Koole, Luc Mortelmans, Felix Mottaghy
Pages: 31 - 31 - Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET(2012)
Authors: Christophe Deroose, Rik Gijsbers, Jan Balzarini, Veerle Baekelandt, Alfons Verbruggen, Johan Nuyts, Zeger Debyser, Guy Bormans, Luc Mortelmans
Pages: 1266 - 1274 - Septic pulmonary embolisms and metastatic infections from methicillin-resistant Staphylococcus aureus endocarditis on FDG PET/CT(2012)
Authors: Olivier Gheysens, Tom Adriaenssens, Steven Pans, Johan Maertens, Marie-Christine Herregods, Paul Herijgers, Willy Peetermans, Luc Mortelmans
Pages: 183 - 183